Articles On Impression Healthcare (ASX:IHL)

Incannex Healthcare share price [ASX:IHL] is up today after its ASX update shows positive results from IHL’s arthritis treatment test. The Incannex share price is up 9.7% as of 3:00pm today... The post Incannex Healthcare Shares Up on Arth...

Special Report: Incannex Healthcare (ASX:IHL) hydroxychloroquine/cannabidiol (CBD) cocktail is turning into a veritable wonder drug – at least in rodents. ... Read More The post Incannex will pursue a SIXTH possible use for its experimental...

Source: Chinnapong,Shutterstock Summary Clinical stage pharmaceutical development player Incannex Healthcare has reported encouraging outcomes for its lead candidate, IHL-675A, from an animal study. The Company updated that these find...

Incannex Healthcare Ltd (ASX: IHL) shares are up again today as the company announced its new CBD-based drug is more effective in treating rheumatoid arthritis than currently available medications. The Incannex share price opened nearly 15...

Positive results from an in vivo study model using Incannex Healthcare’s (ASX: IHL) lead candidate IHL-675A have triggered the launch of a sixth clinical program investigating the benefits of the drug on the treatment of rheumatoid arthriti...

The Incannex Healthcare Ltd (ASX: IHL) share price, which has shot up 310% in the past 12 months, has remained relatively flat in today’s trade. We take a look at the ASX healthcare share’s latest announcement on its accelerated drug study...

Incannex Healthcare (ASX: IHL) has revealed it will work with Monash Trauma Group on an “extensive” in vivo study evaluating the protective effect of IHL-216A in sports concussion. Monash Trauma Group is a specialised team of academic resea...

Shares trading in medicinal cannabinoid producer Incannex Healthcare Ltd [ASX:IHL] share price are flat today, despite posting positive results in its half-yearly report. The IHL share price is up 2.27% to trade at 22.5 cents per share.......

Biotechnology company Greenlab Australia has secured a two-year deal to supply pharmaceutical-grade, cannabinoid products to Australian medicinal cannabis distributor Cannvalate Pty Ltd for sales to approved patients. Under the non-exclusiv...

The share price of Incannex Healthcare Ltd (ASX:IHL) is up a further 15.9%, trading at 25.5 cents. After a dormant period, the IHL share price sprang to life starting in November... The post Incannex Healthcare Share Price up on Positive R...

The Incannex Healthcare Limited (ASX: IHL) share price has hit a 5-year high at 29 cents during early trade. The shares have since retreated back to 26 cents, up 18%. All the excitement comes after the company released an announcement this...

Summary Incannex Healthcare disclosed promising anti-inflammatory properties of IHL-675A for IBD in an animal study. Medicinal cannabis player is continuously examining the findings to identify and protect new IP supporting its commerc...

Special Report: Incannex Healthcare (ASX:IHL) has found a fifth possible use for its hydroxychloroquine/cannabidiol (CBD) cocktail: treating inflammatory bowel disease. ... Read More The post Incannex says its experimental drug cocktail mig...

Incannex Healthcare (ASX: IHL) has been buoyed by the potential of its candidate IHL-675A to become a multi-use medication after receiving positive results from another pre-clinical in vivo trial into the effect of the drug on inflammatory...

Incannex Healthcare (ASX: IHL) has been buoyed by the potential of its candidate IHL-675A to become a multi-use medication after receiving positive results from another pre-clinical in vivo trial into the effect of the drug on inflammatory...

The Incannex Healthcare Ltd (ASX: IHL) share price is soaring today as the company announced that it is mulling a US listing. Shares in the small-cap health care stock are currently trading 12.82% higher as a result. This has held Incannex...

Medicinal cannabinoid company Incannex Healthcare Ltd [ASX:IHL] is one of the leading stocks. At time of writing the IHL share price is up 12.82%, or 2.5 cents, to trade at 22 cents per share, on news that the company is seeking to dual lis...

Special Report: Incannex Healthcare (ASX:IHL) has announced it will explore a dual listing in the United States, a pioneering step ... Read More The post Incannex shares jump as cannabis/psychedelic pharma company explores dual listing on N...

News that an Austrian hospital using medical cannabis to treat patients with COVID-19 has yielded positive results is spurring investor interest in Incannex Healthcare (ASX: IHL), according to the Australian drug developer. News has been ci...

ASX-listed cannabinoid stocks are poised for a resurgence after global biopharmaceutical company Jazz Pharmaceuticals lobbed a US$7.2 billion (A$9.4 billion) offer for UK-based medicinal cannabis drug developer GW Pharmaceuticals amid a sof...

The Incannex Healthcare Limited (ASX: IHL) share price has zoomed up today as the company announced positive results in its drug study results. Shares in the bio tech small cap are currently trading 7.5% higher at 17 cents. What Incannex d...

Summary Cannabinoid medicines manufacturer Incannex Healthcare has received positive outcomes from an in vivo study of its drug, IHL-675A. The encouraging study outcomes would accelerate the expansion of the drug’s potential uses in ot...

Special Report: Incannex Healthcare (ASX:IHL) shares have gained after the pharmaceutical development company announced it has evaluated its proprietary IHL-675A ... Read More The post Incannex says its received results that its cannabinoid...

Clinical stage pharmaceutical development company Incannex Healthcare (ASX: IHL) has received positive results from an additional in vivo study in assessing the anti-inflammatory capabilities of its lead candidate IHL-675A in the prevention...

The December 2020 quarter heralded Incannex Healthcare’s (ASX: IHL) fifth consecutive period of record sales receipts, while it continued to advance its proprietary therapeutics for sleep apnoea, sepsis associated acute respiratory distress...

Summary Incannex Healthcare is engaged in developing pharmaceutical products with significant economic potential. 2020 was a significant period of research success and milestones for Incannex Healthcare, says Joel Latham, CEO and Manag...

On a path to developing a suite of cannabinoid-based medicines aimed at remedying a range of debilitating conditions, pharmaceutical development company Incannex Healthcare (ASX: IHL) has recruited the first batch of patients for its IHL-42...

Summary Incannex Healthcare disclosed positive outcomes for the neuroprotective capability of IHL-216A in animals. The Company received favourable international search report and opinion on the International Patent Application for IHL-...

Special Report: Incannex Healthcare (ASX:IHL) has flagged positive results from its study on brain-damaged rodents, with confirmation that its cannabis-based ... Read More The post US study shows IHL’s CBD treatment is effective in treating...

Incannex Healthcare (ASX: IHL) has revealed more positive in vivo research for its IHL-216A drug, this time regarding traumatic brain injury and has filed a patent application to cover this intellectual property. IHL-216A comprises cannabid...

At time of writing, the share price of Incannex Healthcare Ltd [ASX:IHL] is up more than 20%, trading at 17.5 cents. You can see the sharp rise in the IHL share price on the chart... The post Incannex Healthcare Share Price Up on Clinical T...

Special Report: Incannex Healthcare (ASX:IHL) is partnering with Monash University for a rigorous scientific study into the safety and efficacy ... Read More The post Incannex teams with Monash University to study safety and efficacy of ‘ma...

Summary Incannex Healthcare and Monash University has signed a partnership agreement to perform a Phase 2 for the treatment of generalised anxiety disorder. The trial would enrol 72 patients and include various key innovations in treat...

Incannex Healthcare (ASX: IHL) has partnered with Monash University to undertake a “world first” clinical trial using psilocybin-assisted psychotherapy to treat generalised anxiety disorder. According to Incannex, evidence is building on us...

Cannabis and its derivatives are on their way to being more widely recognised for their medicinal and therapeutic benefits following the drug’s reclassification this week as a non-narcotic. The most widely-used illicit drug lost its status...

Special Report: Medical cannabis company Incannex Healthcare (ASX:IHL) says a mice study has further vindicated its cannabidiol/hydroxychloroquine cocktail,  IHL-675A. The ... Read More The post Incannex says cannabidiol-hydroxychloroquine...

Cannabinoid development company Incannex Healthcare (ASX: IHL) has unveiled the latest test results of its lead drug candidate IHL-675A, which show its anti-inflammatory potency make it an excellent candidate for the prevention and treatmen...

Cannabinoid drug development company Incannex Healthcare (ASX: IHL) could be on the cusp of announcing a significant development in its mission to develop workable cannabinoid treatments for a range of illnesses including respiratory distre...

It’s been a big night for pot stocks in the US. With a nail-biting election that could dramatically impact the future of cannabis legality. But, back in Australia, local pot stock Incannex Healthcare Ltd (ASX:IHL) has had a big day too. The...

Special Report: Incannex Healthcare (ASX:IHL) says its hydroxychloroquine/cannabidiol combination drug IHL-675A is vastly outperforming CBD alone in fighting inflammation in ... Read More The post Inncanex’s anti-inflammatory and COVID-19...

Clinical-stage cannabinoid development company Incannex Healthcare (ASX: IHL) has received positive results from pre-clinical in vitro studies into the anti-inflammatory potency of its lead drug IHL-675A against sepsis-associated acute resp...

Summary Audio Pixels Holdings (ASX:AKP) is bringing new technologies to digital loudspeaker technologies and announced to have achieved its quarterly objectives. Unique medicinal cannabis products developer, Incannex Healthcare Limited...

New changes to medicinal cannabis announced by Australia’s drug regulator last month are more about pharmaceuticalising the plant than making it more accessible, according to an industry expert. Speaking with Small Caps, medicinal cannabis...

Special Report: Incannex Healthcare (ASX:IHL) has reported its best quarter to date from the sales of cannabinoid products, banking $695,000 ... Read More The post Incannex Healthcare books record CBD sales in Q3 appeared first on Stockhead...

The Incannex Healthcare Ltd [ASX:IHL] share price has risen 6.17% today, to trade at 8.6 cents at the time of writing. The Melbourne-based cannabinoid pharmaceuticals company announced record sales for the September quarter of 2020. The pos...

Incannex (ASX: IHL) has reported its highest period of sales for the September period – beating its previous June quarter record. For the three months ending September 2020, Incannex received $695,000 from cash sales of its cannabinoid prod...

The number of new patients trying medicinal cannabis for the first time has risen significantly since Australians first began hunkering down at home to ride out the COVID-19 storm. According to statistics released by the Therapeutics Goods...

Special Report: Incannex Healthcare (ASX:IHL) has received ethics approval to begin a clinical trial testing its oral cannabinoid drug candidate ... Read More The post Incannex receives ethics approval to begin obstructive sleep apnea trial...

Incannex Healthcare (ASX: IHL) has received ethics approval for a phase 2b clinical trial to study the therapeutic benefits of its lead drug IHL-42X on patients with obstructive sleep apnoea (OSA). This is the first trial in the company’s a...

In a move that would appear to enthuse the ASX-listed cannabis stocks, the Therapeutic Goods Administration (TGA) has announced an interim decision to reclassify cannabidiol (CBD) products so they can be purchased over the counter at pharma...